Cambium Bio (ASX:CMB) Margin of Safety % (DCF FCF Based) : N/A (As of Apr. 22, 2025)

View and export this data going back to 2013. Start your Free Trial

What is Cambium Bio Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Cambium Bio's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

Competitive Comparison of Cambium Bio's Margin of Safety % (DCF FCF Based)

For the Biotechnology subindustry, Cambium Bio's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cambium Bio's Margin of Safety % (DCF FCF Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cambium Bio's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where Cambium Bio's Margin of Safety % (DCF FCF Based) falls into.

Save Embed

;

Save Embed

;

Cambium Bio Margin of Safety % (DCF FCF Based) Related Terms

Thank you for viewing the detailed overview of Cambium Bio's Margin of Safety % (DCF FCF Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

Cambium Bio Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cambium Bio Ltd (ASX:CMB) » Definitions » Margin of Safety % (DCF FCF Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

16 Goodhope Street, Paddington, Sydney, NSW, AUS, 2021

Website

https://www.cambium.bio

Cambium Bio Ltd is a clinical-stage regenerative medicine company in Australia. It focuses on the development of biologics for ophthalmology and tissue repair applications. Its technology platform is based on human platelet lysate, which is being leveraged to create a pipeline of novel therapeutics, with a primary focus on ophthalmology. The company's product candidate Elate Ocular is being developed to address unmet medical needs in the treatment of dry eye disease. In addition, its stem cell platform, Progenza, is being applied to the development of therapies for knee osteoarthritis and other tissue repair indications.

Cambium Bio Headlines

No Headlines